Emerging Translational Opportunities in Comparative Oncology With Companion Canine Cancers: Radiation Oncology. by Nolan, Michael W et al.
UC Davis
UC Davis Previously Published Works
Title














eScholarship.org Powered by the California Digital Library
University of California
REVIEW
published: 22 November 2019
doi: 10.3389/fonc.2019.01291
Frontiers in Oncology | www.frontiersin.org 1 November 2019 | Volume 9 | Article 1291
Edited by:
Mark W. Dewhirst,
Duke University, United States
Reviewed by:
Maria Shoshan,
Karolinska Institutet (KI), Sweden
Karishma Rajani,








This article was submitted to
Cancer Molecular Targets and
Therapeutics,
a section of the journal
Frontiers in Oncology
Received: 27 August 2019
Accepted: 07 November 2019
Published: 22 November 2019
Citation:
Nolan MW, Kent MS and Boss M-K
(2019) Emerging Translational
Opportunities in Comparative





in Comparative Oncology With
Companion Canine Cancers:
Radiation Oncology
Michael W. Nolan 1,2,3*, Michael S. Kent 4 and Mary-Keara Boss 5
1Department of Clinical Sciences, North Carolina State University, Raleigh, NC, United States, 2Comparative Medicine
Institute, North Carolina State University, Raleigh, NC, United States, 3Duke Cancer Institute, Duke University, Durham, NC,
United States, 4Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California,
Davis, Davis, CA, United States, 5Department of Environmental and Radiological Health Sciences, Flint Animal Cancer
Center, Colorado State University, Fort Collins, CO, United States
It is estimated that more than 6 million pet dogs are diagnosed with cancer annually in
the USA. Both primary care and specialist veterinarians are frequently called upon to
provide clinical care that improves the quality and/or quantity of life for affected animals.
Because these cancers develop spontaneously in animals that often share the same
environment as their owners, have intact immune systems and are of similar size to
humans, and because the diagnostic tests and treatments for these cancers are similar
to those used for management of human cancers, canine cancer provides an opportunity
for research that simultaneously helps improve both canine and human health care. This
is especially true in the field of radiation oncology, for which there is a rich and continually
evolving history of learning from the careful study of pet dogs undergoing various forms
of radiotherapy. The purpose of this review article is to inform readers of the potential
utility and limitations of using dogs in that manner; the peer-reviewed literature will be
critically reviewed, and current research efforts will be discussed. The article concludes
with a look toward promising future directions and applications of this pet dog “model.”
Keywords: radiation oncology, radiobiology, canine comparative radiation oncology, medical physics, animal
models of cancer, imaging, theranostics, translational research
INTRODUCTION
Radiotherapy (RT) is most frequently applied to pet animals with naturally-occurring cancer as
a means for improving animal health. However, there is also a long and rich history of studying
radiation responses in the tumors and normal tissues of dogs, with a goal of informing therapeutic
development in a manner that directly benefits both canine and human cancer patients. Such
research forms the basis for the field of canine comparative radiation oncology and radiobiology.
The purpose of this review article is to inform readers of the potential utility and limitations of using
dogs in that manner; the peer-reviewed literature will be critically reviewed, and current research
efforts will be discussed. The article will conclude with a look toward promising future directions
and applications of this pet dog “model”; but we will begin with a brief overview of current practices
in veterinary radiation oncology, which will enable readers to gain an appreciation for how the field
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of canine comparative radiation oncology has developed, and
how canine cancer studies can be efficiently, effectively and
ethically conducted.
The American Veterinary Medical Association estimated that
38% of households in the Unites States owned a pet dog in
2018, and the National Cancer Institute’s Comparative Oncology
Program reports that nationwide ∼6 million new canine cancer
diagnoses are made annually. RT is an important component of
cancer care for dogs; external beam RT is the most common form
of treatment. But despite the high rate of canine cancers, and
the efficacy of RT, it is actually quite uncommon for dogs to be
treated as such; this is largely attributable to limited accessibility.
Financial cost is another important barrier to pet owners who
might otherwise want to pursue advanced cancer treatments. The
economics of veterinary RT are not well-documented. The cost of
care varies with geographic location and type of center (university
run academic veterinary teaching hospitals vs. private practice
specialty clinics), but anecdotally, a course of palliative-intent
RT in the US currently costs between ∼$1,000 and $3,500, and
the cost for a definitive-intent course of therapy is often between
$5,000 and $12,000. This is challenging because fewer than 10% of
households carry pet health insurance, and so for most families,
veterinary care represents an out-of-pocket expense. Another
important factor that limits accessibility is the distance that must
be traveled to pursue care; a 2010 report identified 66 veterinary-
specific external beam RT centers in the United States (1). While
that number is low relative to the number of canine cancer
cases, geographic access is improving; indeed, there were only 42
US-based veterinary RT centers in 2001 (2).
Dogs develop a wide range of neoplasms that are treated with
RT. Some of the most common indications with translational
relevance to humans include soft tissue sarcoma, extremity
osteosarcoma, glioma, and genitourinary carcinomas (both
muscle-invasive urothelial carcinomas of the urinary bladder,
and prostatic carcinomas). Many of these canine cancers share
striking similarities with the equivalent human diseases, not
only clinically and histologically, but also at a molecular and
genomic level. For example, the most commonly altered gene
in both canine and human osteosarcoma is TP53; the genomic
imbalance in the two species is similar, and expression of
several genes (including PTEN and RUNX2) are correlated
with ploidy (3–5). Likewise, in addition to certain similarities
between human and canine glioma, the process of PDGF-
induced gliomagenesis seems to be well-conserved across
mammalian species (6, 7).
A majority of canine radiotherapy patients are treated
using conventional C-arm linear accelerators. Due to the need
for general anesthesia, full-course definitive-intent, treatment
protocols tend to be hypofractionated relative to protocols in
common use for humans; often a total of 16–20 daily (Monday
through Friday) fractions are administered, with fractional doses
used for dogs typically ranging from 2.5 to 4Gy. As with
physician-based oncology, there has also been a tremendous shift
in recent years toward much higher doses per fraction, with
a rapid increase in access to, and application of, stereotactic
radiosurgery (SRS) and stereotactic body RT (SBRT) for various
malignancies (1).
HISTORICAL USES OF DOGS IN
TRANSLATIONAL RADIATION RESEARCH
Normal Tissue Toxicity
In an online query of the US National Library of Medicine’s
PubMed database for the terms “canine” and “radiation,”
the earliest return was a 1922 article that was written by
Stafford Warren and George Whipple; it was published in
the Journal of Experimental Medicine, and described small
intestinal radiosensitivity in dogs (8). This early use of dogs for
radiobiology research may have been driven at least in part by the
ease of housing and handling dogs, as well as access to hospital-
grade irradiation equipment (X- and gamma-ray) for which it
would have been straightforward to perform partial or total body
irradiations. The similar anatomy of dogs and humans would also
have been favorable, thus allowing experiments to be performed
with similar radiation field sizes, and targets, as compared with
other research species of the times, including various large animal
agricultural species (e.g., swine, cattle) and small fish (9–11).
Fortuitously, it was later learned that DNA repair mechanisms
are highly conserved between mammalian species, and that there
is high homology between key DNA damage response genes in
humans and dogs (12–14).
Dogs have been used to model radiation injury in a wide
range of normal tissues. And indeed, just as veterinarians have
borrowed from physicians to inform the practice of veterinary
radiation oncology, lessons learned from canine radiobiology
research have also had important influences to optimize human
cancer care. Through the 1980’s and 1990’s significant efforts
at both Colorado State University and the National Cancer
Institute (NCI) were directed toward defining the tolerance of
canine tissues to intra-operative RT (IORT); similar studies were
performed with multi-fraction irradiation protocols to estimate
alpha-to-beta ratios for various normal tissues. These studies
evaluated both conventional pathologic endpoints, and a wide
range of clinically-relevant functional endpoints. For example,
in a canine study, the volume of lung irradiated was found to
be a critical limiting factor in thoracic RT (15). The assumption
had already been made that a dose-volume relationship existed
for lung tissue (16); the TD50/5 (the radiation dose that causes
toxicity in 50% of patients, 5 years after irradiation) was estimated
to be 65Gy when 33% of the total lung volume was irradiated.
However, there were no cases of severe symptomatic pneumonitis
in dogs for whom 33% of lung received up to 72Gy; this suggests
that when patients have otherwise healthy lungs (with normal
compensatory function) the dose tolerance limits for lung may
actually be higher than those originally proposed by Emami
et al. (16).
It is beyond the scope of this manuscript to review all
normal tissue injury studies for which dogs were utilized;
however, another noteworthy endeavor was the use dogs to
investigate tolerance of peripheral nerves to IORT. In the
1990’s, investigators at NCI demonstrated a progressive sciatic
neuropathy in American Foxhounds: with 3.5 years of follow-
up, doses of up to 20Gy were not found to cause clinically
significant neuropathies, but 5 years after irradiation, doses of
15Gy or more of IORT were injurious (17, 18). Similar findings
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were reported in beagles, whose nerve function was evaluated via
histology, neurologic examination, and electrophysiology (19).
These experiments confirmed that nerves are dose-limiting for
IORT, and that the neurovasculature plays a critical role in nerve
injury. These studies also yielded insight regarding combinatorial
therapies; while combining IORT with external beam RT resulted
in a similar incidence and latency of neuropathy vs. IORT
alone, the combination of IORT with hyperthermia led to
increased incidence and decreased time to onset of nerve damage.
More recently, hounds were used to demonstrate that both
altered function of the internal pudendal artery, and pudendal
nerve, accompany erectile dysfunction that follows treatment of
prostate cancer with SBRT (20). That study identified potential
strategies for mitigating radiation-induced sexual dysfunction in
men. It also provided data to support the clinical observation
that high-dose SBRT may lead to severe colorectal injury, for
which latency can be increased, and incidence reduced via either
reduction of the radiation dose, or increasing the duration of the
interfraction interval (21, 22).
While some laboratory groups have studied both purpose-
bred and tumor-bearing pet dogs, the latter have largely been
used to study radiation effects on tumors, rather than normal
tissue. Rainer Storb’s team at the Fred Hutchinson Cancer
Research Center has taken this approach for many years,
demonstrating dose, fractionation and dose rate effects of total
body irradiation in research colony animals, and providing
proof-of-principle for clinical applications in the management of
lymphomatous diseases in pet dogs (23–36). With rising clinical
interest in bone marrow transplantation (including total body
irradiation for marrow ablation) in pet dogs with high grade
(non-Hodgkin’s) multicentric lymphomas, opportunities exist to
test novel radiomitigators (37). Certainly, infrastructure exists to
enable canine clinical trials to study radiation-modifying drugs
and devices. A classic example is a 1986 paper describing the
role of canine comparative radiation oncology research in early
development of the FDA-approved radioprotector amifostine
(WR-2721); a bi-institutional canine clinical trial was performed,
in which 73 pet dogs with spontaneously occurring soft tissue
sarcomas were randomized (over a period of 3 years) to two
dose response assays to receive irradiation alone, or with the
radioprotector WR-2721 (38). With the dose and schedule used
(40mg/kg given intravenously, 15min before each of 10 radiation
fractions), WR-2721 provided no protection against acute skin
reactions, little to no protection against late complications, and
there was a suggestion that the drug protocol provided protection
of the tumors at the low end of the radiation dose range. A
contemporary example of how a similar study design can be
deployed is provided by ongoing research by two authors of
this review; both Nolan and Boss are involved in an NIH-
sponsored bi-institutional canine clinical trial (5R01CA232148-
02) which is currently enrolling 104 dogs with spontaneously
occurring soft tissue sarcomas (over a 5 year period) to
determine the safety of, and radiation enhancement provided by
ultrasound-guided oxygen release from microbubbles. Conduct
of these large-scale studies has historically been overseen and
facilitated by clinical study coordinators and study teams at
the local institutions. Today, large-scale multi-center trials can
be coordinated by the Comparative Oncology Program (COP),
which is a core resource of the Center for Cancer Research
at the National Cancer Institute. The COP centrally manages
a network of 20 academic comparative oncology centers; these
centers comprise the Comparative Oncology Trials Consortium
(COTC). Similarly, and with support from the V-Foundation, a
second trials network is currently being planned. As envisioned,
that group, called the Canine Oncology Research Consortium
(CORC), will include multiple academic partners, with each
partner defined as an academic veterinary center paired with
an NCI-designated Comprehensive Cancer Center. Both the
COP/COTC and CORC exemplify the expanded support that
is now available for efficient conduct of canine comparative
oncology clinical trials.
Another contemporary example of how normal tissue toxicity
data can be directly gathered from pet dogs is provided by an
author of this review; while not yet published, Nolan et al.,
have presented an abstract which describes how pain can
be measured and modeled in dogs in pet dogs that develop
acute radiodermatitis while undergoing post-operative RT for
incompletely excised extremity soft tissue sarcomas (39). Their
work not only indicated that mechanical quantitative sensory
testing can be used as a reliable tool for preclinical evaluation
of novel analgesic strategies, but also provides evidence that
localized RT-induced pain is accompanied by widespread
somatosensory sensitization. That set of experiments provides a
template for how pet dog studies might fit into the traditional
paradigm of therapeutic development: (1) hypothesis generating
observations can first be made in people or dogs undergoing
cancer therapy; (2) mechanistic studies can then be performed
in more conventional preclinical models; (3) novel therapies that
arise from the preclinical work can then be efficiently testing in
dogs, to provide proof-of-concept for safety and clinical efficacy,
before advancing to early phase human clinical trials.
Tumor Microenvironment
Tumor hypoxia is associated with relative radioresistance and
aggressive biological behavior. Canine comparative oncology
research has contributed meaningfully to the advancement of
radiobiology research through tumor oxygenation studies. To
validate canine cancer as a translationally relevant model of
tumor hypoxia, Cline et al. detected the in vivo binding of a
2-nitroimidazole hypoxia (CCI-103F) marker in histochemical
sections of canine tumors (40). The binding pattern was
consistent with the expected location of hypoxic cells in tissues
for which oxygen concentration gradients have been established
by diffusion. The hypoxic fractions appeared in regions adjacent
to necrosis, but also in regions free of necrosis. In addition
to interest in hypoxic cells, populations of both non-cycling
quiescent cells and rapidly-cycling proliferating cells can also
influence tumor radioresponses. Zeman et al. investigated the
relationships between hypoxia and proliferative status semi-
quantitatively via immunohistochemical analysis of CCI-103F
and proliferating cell nuclear antigen (PCNA), respectively,
in canine tumor samples (41). Tumors with both high and
low hypoxic and proliferative area fractions were identified;
the hypoxic and proliferative cell populations overlapped to
varying extents.
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Direct, real-time quantification of tissue oxygenation was
enabled by emergence of the Eppendorf method of direct
oxygen partial pressure measurements. This technique, which
involves intratumoral placement of polargraphic oxygen needle
electrodes, opened the door for comparative veterinary trials
characterizing the tumor microenvironmental effects of hypoxia
in spontaneous canine tumors; it also allowed trials designed
to investigate the impact of tumor oxygenation on treatment
outcomes. Achermann et al. evaluated the oxygenation of canine
soft tissue sarcomas via the Eppendorf method and determined
that 44% of tumors had oxygenation measurements consistent
with hypoxia (42). Soon after, trials were performed in dogs
undergoing fractionated RT. Polarographic needle electrodes
and OxyLite fluorescence probes were used to document the
presence and changes of hypoxia during fractionated RT; 58%
of the dog tumors in one study were hypoxic prior to treatment
(43). The pO2 of initially hypoxic tumors remained unchanged
during fractionated RT, whereas the pO2 decreased in initially
normoxic tumors. Brurberg et al. evaluated pO2 fluctuations
in spontaneous canine tumors prior to and during RT (44). It
was found that overall oxygenation status differed substantially
among the tumors, and RT had no consistent effect on overall
oxygenation status. Fluctuations in pO2 were detected in both
unirradiated and irradiated tumors, and those fluctuations were
independent of the baseline tumor oxygenation status. This
study was important as it demonstrated for the first time
in canine cancer the dynamic changes in tumor oxygenation
in spontaneous tumors over an extended time period. The
influence of tumor oxygenation status on the response to
RT was first described for spontaneous canine tumors by
Bley et al. (45). Pretreatment oxygen level measurements in
spontaneous canine tumors were correlated with local tumor
response after RT; after curative-intent full-course irradiation,
hypoxic tumors had a significantly shorter median progression-
free interval and a shorter overall survival time compared to
better oxygenated tumors.
Comparative canine oncology trials were instrumental to
understanding how hyperthermia can be combined with RT
to improve tumor control. A number of positive randomized
studies in dogs provided initial evidence supporting the
therapeutic benefit of such combinatorial therapy (46–48). In
canine soft tissue sarcomas (STS), Vujaskovic et al. identified
changes in tumor oxygenation, extracellular pH, and blood flow
after hyperthermia (49). They also found that hyperthermia
has biphasic effects on tumor physiologic parameters: lower
temperatures tend to favor improved perfusion and oxygenation,
whereas higher temperatures are more likely to cause vascular
damage, leading to greater hypoxia.
EMERGING USES OF DOGS IN
TRANSLATIONAL RADIATION RESEARCH
Imaging/Theranostics
Canine comparative oncology studies that incorporate functional
imaging technologies have been used to characterize the tumor
microenvironment, improve target delineation, optimize
biological dose delivery, and correlate imaging characteristics
with clinical outcomes. Building upon the early oxygenation
and radioresponse research which relied on tissue sampling
or direct insertion of electrodes for measurements, functional
imaging studies provide opportunities for serial, non-invasive,
quantitative or semi-quantitative analyses of the tumor
microenvironment without tissue disruption (Figure 1).
Various positron emission tomography (PET) radiotracers
have been used in comparative oncology studies to characterize
the tumor microenvironment. The glucose analog 2-deoxy-2-
[18F]-Fluoro-D-glucose (FDG), a marker of glucose uptake, is
the most commonly used PET tracer in clinical oncology, and
canine cancer patients were among the earliest to be imaged with
FDG PET (51). FDG PET/CT has become increasingly available
in veterinary medicine (52), and it has been used to characterize
tumor biology and treatment responses (53–57).
As tumor hypoxia is associated with both radioresistance
and tumor aggressiveness, PET-based approaches have been
developed for measuring tumor hypoxia (Figure 2). Bruehlmeier
et al. were the first to examine tumor hypoxia in canine STS
using [18F]-fluoromisonidazole ([18F]-FMISO); FMISO tumor
oxygenation measurements correlated well with Eppendorf
electrode measurements (58). However, when evaluating tumor
hypoxia via [18F]-FMISO in cats with fibrosarcomas, the
polarographic pO2 measurements did not confirm PET results;
this lack of concordance was attributed to extensive tumor
necrosis, and heterogeneous patterns of hypoxia (59). An
alternative hypoxia imaging tracer is 64Cu-ATSM. Hansen
et al. performed a study to compare uptake characteristics
of pimonidazole immunohistochemistry (IHC) to 64Cu-ATSM
autoradiography, and to PET uptake levels of 64Cu-ATSM and
[18F]-FDG in spontaneous canine sarcomas and carcinomas (60).
Tumors with high levels of pimonidazole staining displayed high
uptake of [18F]-FDG and 64Cu-ATSM; the regional distribution
of 64Cu-ATSM and pimonidazole correlated with each other in
heterogeneous tumor regions. The potential of using 64Cu-ATSM
to characterize the tumor microenvironment longitudinally over
time was evaluated in canine tumors by measuring tumor uptake
and distribution characteristics between consecutive PET scans
(61). In this study, 64Cu-ATSM uptake was also compared to
uptake and spatial distributions of [18F]-FDG and dynamic
contrast enhanced perfusion CT perfusion maps. 64Cu-ATSM
uptake was positively correlated to FDG, signal was relatively
stable between PET scans, and temporal changes were observed
in hypo-perfused regions. 64Cu-ATSM PET/CT scan has also
been used to detect hypoxia in feline head and neck squamous
cell carcinoma (HNSCC), with PET/CT results verified by
pimonidazole IHC and O2 detection probes (62).
Comparative canine oncology trials have supported
investigations into the kinetics of established and novel PET/CT
approaches, as well as characterization of the spatial distribution
of these biological markers (63–65). Bradshaw et al. concurrently
evaluated the predictive value of numerous quantitative imaging
biomarkers derived from multitracer PET imaging in tumors
before and during RT in dogs with sinonasal tumors (66).
The strongest predictors of poor outcome were derived from
fluorothymidine (FLT) imaging, a marker of proliferation. The
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FIGURE 1 | Cherenkov imaging represents a non-invasive method for quantification of tumor oxygenation during radiation delivery, and is currently being validated in a
canine clinical trial (50). (A) camera setup for Cherenkov image acquisition during irradiation of a soft tissue sarcoma on the right shoulder of a dog, including a
clear/colorless 1 centimeter thick bolus material overlying the tumor and used for radiation dose-buildup; (B) “camera’s-eye” view of the irradiation target—fur
overlying the tumor has been removed; (C–E) representative Cherenkov images taken during a single radiation fraction that was delivered using the setup depicted in
(A,B); (F) relative to stable normal tissue (NT) oxygenation, reductions in both Oxylite measurements and Cherenkov intensity within the tumor region of interest (ROI)
demonstrate that the tumor became progressively more hypoxic during delivery of this 6Gy radiation fraction. Subtle visible changes within the tumor ROI (the
centrally-located light areas on Cherenkov images C–E) correspond to reductions in signal intensity (subfractions 1–3, respectively, on the graph) that were measured
using digital image processing tools (images courtesy of Ashlyn Rickard, Duke University).
combination of high mid-treatment standardized uptake values
(SUVmax) and large decreases in FLT signal from pretreatment
to mid-treatment was associated with worse clinical outcome. In
this study, neither FDG PET nor Cu-ATSM PET were predictive
of outcome. PET/CT has also been utilized in comparative
oncology studies to investigate the potential for radiation “dose
painting,” which aims to improve therapeutic outcomes by
increasing radiation dose in tumor regions that are identified
as being at risk of relative radioresistance based upon imaging
features (67, 68). Early results have been mixed.
Dynamic contrast-enhanced magnetic resonance imaging
(DCE-MRI) can be used to assess tumor physiology by
exploiting abnormal tumor microvasculature (Figure 3). This
enables quantitative assessment of tissue vessel density, integrity,
and permeability (69). In a canine STS study, DCE-MRI was
performed before and following the first hyperthermia treatment,
and parameters associated with increased tumor perfusion were
predictive for overall and metastasis-free survival (70). This was
the first time that DCE-MRI was shown to be predictive of
clinical outcome for STS. A subsequent study performed an
integrative analysis of gene expression and diffusion weighted
imaging (DWI) parameters, pre- and post-treatment, in dogs
with STS treated with thermoradiotherapy. DWI is an MRI-
based technique which quantifies the diffusion of water to
characterize tumor tissue (71). Significant correlations were
identified between gene expression and DWI. An unsupervised
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FIGURE 2 | [18F]-FAZA PET scan images from a dog with a squamous cell
carcinoma on the ventral aspect of the tongue. The areas depicted in red have
high uptake of the tracer, indicating hypoxia; the yellow and green regions
have intermediate uptake, and the blue areas have low tracer uptake, thus
indicating the presence of well-oxygenated tissue.
analysis of the gene sets revealed two clusters: (1) tumors with an
increase in tissue water content (corresponding to an increased
ADC on the DWI) after treatment showed increases in genes
associated with tissue remodeling (e.g., IL1β, IL6, IL8, IL10) and
inflammation (e.g., MMP1, TGFβ); (2) tumors with less change
in the ADC had more signs of more mature vasculature (i.e.,
higher gene expression of CD31 and vWF). These observations
demonstrated how one can link changes in tumor physiology to
changes in gene expression. This work demonstrates how early
changes in functional imaging parameters might be used to aid in
prognostication. Furthermore, the authors provided a blueprint
for how such data can be manipulated to identify potential new
drug targets.
DNA Damage Responses
The DNA damage response (DDR) is a complex network of
pathways that responds to both endogenous and exogenous DNA
damage. DDR deficiencies can be targeted for cancer therapy.
For example, the DDR can be inhibited as a radiosensitization
strategy. Additionally, because DNA damage drives chronic
inflammation and various molecular and cellular pathways of
the DDR activate immune signaling (72) and since checkpoint
inhibitors may work best in the setting of tumors with high
mutation load, DDR inhibition during RT can generate and
preserve treatment-induced DNA damage which sensitizes the
tumor to subsequent checkpoint blockade (73). There are many
DDR components that can be inhibited to sensitize cancer cells to
DNA damaging agents, including PARP, DNA-PKcs, ATM, ATR,
Chk1, and Chk2.
Many novel agents that show great promise in mice ultimately
fail to prove efficacious in humans. Despite improved rodent
models, methodologies, and study designs, many factors still
contribute to these failures (74). With specific regard to DDR
modifiers, a recent review suggested that better predictive
biomarkers are needed to identify patients that would benefit
from treatment, and that better therapeutic response biomarkers
are also needed to quantify the pharmacodynamic impact and
clinical gains that are achieved in humans (75). Successful and
efficient translation of DDR inhibitors will rely upon preclinical
studies that are designed to evaluate appropriate endpoints that
can also be measured in human trials; when possible, they should
also determine whether synthetic lethality contributes to efficacy
of the drug as a chemo-radiosensitizer.
Dogs have previously been proposed as a model for studying
the DDR (76). Indeed, the intrinsic radiosensitivity of various
canine tumors and tumors cell lines is increasingly well-
understood (77, 78), and methods for measuring the canine DDR
have also been developed, including validation of the comet assay
and immunohistochemistry for phosphorylated H2AX (79).
Canine extremity osteosarcoma (OS) may be particularly
useful in the development of novel DDR inhibitors that can
be combined with RT—ATR, ATM, and DNA-PK inhibitors
in particular. As with pediatric OS, tumor resection plus
chemotherapy is the standard treatment for canine OS. However,
because RT can also provide significant analgesia and local tumor
control, and because tumor necrosis is a validated surrogate for
local control of canine OS, an intriguing study design would
be to treat OS-bearing dogs with chemoRT, with or without a
novel DDR inhibitor, and subsequently pursue tumor removal to
provide standard-of-care treatment to the dog, and to provide
investigators access to the resected tumor, which would thus
allow robust measurement of treatment effects. Furthermore,
approximately half of canine OS tumors have aberrant p53
function, making it possible to compare the effects of chemo-
radiosensitizing effects of ATR or DNA-PK inhibition in normal
tissues and tumors that may or may not benefit from synthetic
lethality (80, 81). Thus, by studying canine OS, investigators
would be able to learn about both mechanisms of interaction and
clinically relevant biomarkers that directly translate to a variety
of human cancers in a manner that is essentially agnostic of
tumor histology.
Immuno-Radiotherapy
Advanced metastatic disease is the most common cause of death
in human patients and is a significant cause of death in dogs
as well (82). Cancer immunotherapy is not a new concept, but
interest re-emerged when in 2010 a phase 3 clinical trial in
people with metastatic melanoma showed a survival advantage
for those treated with ipilimumab, a monoclonal antibody that
targets CTLA-4 (83). Since then, the use of immunotherapy in
human clinical trials has expanded rapidly, with some amazing
successes. The problem remains that the majority of patients do
not respond favorably; furthermore, unacceptable and sometimes
fatal toxicities have occurred (84, 85).
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FIGURE 3 | Canine soft tissue sarcoma. Pre-treatment quantification of iAUGC100 (initial area under the gadolinium concentration vs. time curve; this is a
semi-quantitative parameter defined as a measure of the amount of contrast agent delivered to and retained by a tumor in a given time period). Outlined area
represents the region with reduced perfusion and suspected hypoxic tissue. Radiation dose could be intensified to this area with the attempt to improve treatment
outcome to suspected resistant tumor cell population. With permission from Boss et al. (69).
The idea that RT could induce a tumor response distant from
the irradiated field has been around since the 1950s when the so-
called “abscopal effect” was first proposed (86). In the context of
RT, the abscopal effect refers to regression of metastatic lesions
that are distant from the primary tumor and irradiated field.
These are rare events; one study found 46 cases reported in the
literature between 1969 and 2014 (87). That the abscopal effect
occurs secondary to an immune response was first demonstrated
in a 2004 mouse study which characterized radiation-induced
abscopal effects as being a T-cell dependent event (88). Since that
time it has become obvious that the mechanism is actually more
complex, and involves a multi-faceted immune response (89).
While local irradiation can result in immunogenic cell
kill by releasing neoantigens and creating local inflammation,
irradiation can also attract immunosuppressive cells into
the tumor microenvironment. This includes myeloid-derived
suppressor cells, M2 tumor-associated macrophages and T
regulatory cells; this cellular response is associated with release
of cytokines (e.g., TGF-β and IL-10) which causes local
immunosuppression (90). Given the clinical rarity of measurably
and clinically beneficial RT-induced immune responses, and
because of the potential for post-irradiation immunosuppression,
it is logical that patients may benefit from a combination of
RT plus immunotherapeutics that can more reliably induce
beneficial systemic immune responses (91).
The dog immune system has been fairly well-characterized
and shows great homology to humans (92). Because of these
similarities, pet dogs with cancer can provide a useful model
when looking to translate potential new radioimmunotherapies
from mouse studies to human clinical trials.
Several small clinical trials using radio-immunotherapy
protocols in dogs have been published. One recent example
involved testing a novel immunotherapy combination in
dogs with metastatic melanomas and sarcomas. Immediately
after each fraction of primary tumor irradiation, intratumoral
injections of canine CpG oligodeoxynucleotides [CpG ODNs;
immune stimulatory toll-like receptor 9 (TLR9) agonists] were
done; dogs were also orally dosed with 1-methyl-tryptophan [an
indolamine-2,3 dioxygenase (IDO) inhibitor] (93). The idea was
that localized tumor irradiation would induce immunogenic cell
death, the CpG ODNs would stimulate an immune response,
and the IDO checkpoint inhibitor would counter tumor-induced
immunosuppression. The dog trial was paired withmouse studies
which revealed a rebound immunosuppression after mice were
treated with radiation or CpG ODNs alone. While all dogs
showed a local response to irradiation, there were also abscopal
responses in their metastatic lesions with one dog having a
complete response, two having partial responses, one with stable
disease and one with progressive disease (Figure 4). There was
no toxicity beyond what was expected for a palliative course
of localized RT. Interestingly, both circulating and tumoral T
regulatory cells were decreased in the dogs who responded and
increased in the dog with progressive disease—suggesting this as
a potential biomarker. Due to the promising preliminary results
and the lack of toxicity in dogs a clinical trial using this same
strategy has now opened for people with advanced metastatic
cancers (94).
In another study using an adoptive immunotherapy approach
combined with RT, dog natural killer cells were isolated from
peripheral blood (95). Those cells could be expanded and
activated, and NK cells were capable of killing osteosarcoma
tumor cells in vitro. Furthermore, cytotoxicity was improved
when tumor cells were pretreated with ionizing radiation. This
was repeated in vivo using canine patient-derived xenograft
(PDX) tumors; adoptively-transferred canine NK cells delayed
the growth of tumors in mice, and focal irradiation increased
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FIGURE 4 | Computed tomographic image of a dog’s lungs showing a metastatic lesion (arrow) taken prior to local irradiation of an oral tumor (A) and 3 months post
treatment (B) showing an abscopal effect with near complete resolution of the mass.
NK cell homing to these sarcoma xenografts. As part of the same
study, a proof of concept clinical trial was carried out in 10 dogs
with osteosarcoma. Treatment consisted of a course of palliative-
intent RT followed by two intra-lesional injections of autologous
activated canine NK cells. The NK cells were isolated, expanded,
and activated ex vivo and supplemented with rhIL-2. The study
demonstrated that NK cells persisted at the local tumor site for
at least 1 week after injection. There was acceptable toxicity and
in one of the cases there was resolution of a suspected metastatic
lung nodule suggesting a possible abscopal effect.
Despite these early successes, there are several challenges in
carrying out immune-RT trials in dogs, including: (1) limited
availability of validated reagents, canine-specific monoclonal
antibodies, and canine interleukins; and (2) limited access to
properly staffed and equipped veterinary radiation oncology and
RT centers (92).Work is ongoing to better characterize the canine
immune system, and while many canine-specific antibodies are
still not commercially available, this is improving. The majority
of available checkpoint inhibitors are humanized monoclonal
antibodies for which commercially available caninized versions
do not exist. Furthermore, while it is possible to use recombinant
human interleukins in dogs (they have been shown to be
effective), there is concern that with prolonged use dogs
could develop neutralizing antibodies and/or adverse immune
reactions to the human-derived products. Thus, it will be
difficult to fully realize the potential of this model until more
immunotherapies become available for safe use in dogs.
FUTURE DIRECTIONS
The existing experimental animal models (e.g., rodents,
zebrafish) are, and will remain, vitally important for in vivo
radiation oncology research. Yet, there are opportunities in
using pet dogs that have not been fully explored; pet dogs with
spontaneously arising tumors can better inform the use of RT for
clinical management of various human cancers. All of the topics
discussed above will continue to spawn new research. Some
of the additional areas where companion animal studies could
make an impact in human medicine include radiobiology studies
looking at different dosing and fractionation schemes, in vivo
dosimetry, and testing of newly developed radiation sensitizing
and radiation mitigating agents.
Small animal irradiators used in rodent research are
increasingly sophisticated, but remain unable to recapitulate
medical linear accelerators in terms of beam energy and dose
rate (96, 97). Because companion animal oncology patients
are routinely treated using standard clinical linear accelerators,
they are also readily available for studies that seek to better
understand the radiobiological effects of such factors as spatial
fractionation (e.g., GRID and Lattice RT) and dose rate
(e.g., FLASH-RT) (98, 99). For example, canine tumors are
particularly well-suited to understanding the underlying biology
of FLASH-RT. This is because the apparent selective normal
tissue sparing (vs. tumor sparing) achieved by FLASH-RT is
likely dependent upon pO2; and as discussed above, because
the size and growth rate of canine tumors is more similar
to human cancers than experimentally-induced tumors in
rodents, the oxygen (hypoxia) profiles of canine tumors also
tend to be similar to those of human tumors. FLASH-RT
also provides a particularly good example of how studies in
companion animal species can be used as an intermediate
step in scaling technologies from geometries that work for
rodents, to those that would work well in the context of human
tumors (100). In much the same way that treatment of canine
intranasal tumors was used in the early development of helical
Tomotherapy, these types of companion animal studies provide
an excellent vehicle for testing the safety of, and establishing
feasible clinical workflows for, novel treatment devices and
approaches (101).
One area where dog studies may be particularly useful is
understanding the interplay between radiation dose and immune
responses. Some in vivo work suggests that the ideal fractional
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dose for radioimmunotherapy may be 6–8Gy per fraction,
rather than the more extreme doses that are commonly used in
modern SRS/SBRT (89, 102). Interestingly, a recent study showed
an inverse relationship between radiation dose and survival
in humans having undergone RT for stage III non-small cell
lung cancer; worsening outcomes with increasing radiation dose
was counterintuitive but may have been attributable to delivery
of higher radiation doses to tumor-infiltrating immune cells.
Hypofractionation is commonly used in veterinary medicine
both for palliation, and in SRS/SBRT; this practice pattern makes
it relatively straightforward to interpose scientific research into
clinical practice in order to use dogs as a model for studying the
biology of hypofractionation.
Research in the field of therapeutic radiation physics could
also benefit from a canine comparative radiation oncology
approach. Because of similarities between human and canine
anatomy and treatment approach, dogs can be a valuable model
for validation of new techniques and methods; this use of canine
comparative radiation oncology research has been exemplified
for in vivo dosimetry (103).
There are also several limitations of the canine “model” that
must be addressed. First, access to clinical outcomes data, and
canine cancer tissues is limited; at the present time, there are no
canine cancer registries in the United States, there are few well-
validated canine cancer cell lines, and there are very few well-
curated canine cancer tissue banks exist. Second, while dogs and
their cancers more closely recapitulate the geometry of human
cancers than do tumors of rodents, it should be noted that
many pet dogs weigh far less than half the average human adult.
Third, while there are many similarities between various human
and canine malignancies, important differences also exist. For
example, while human prostate cancer most often arises from
the glandular acini, carcinomas of the canine prostate seem to
most often be of urothelial origin. And although IDH1 and
IDH2 mutations are frequent in human gliomas, they are not
a consistent or common feature of the canine condition (104).
The value of any model system is maximized by understanding
its strengths and limitations; thus, moving forward, it will be
of utmost importance to focus significant energy on describing
the biology of canine cancers, and making rigorous comparisons
with the analogous human conditions.
Though the field of canine comparative radiation oncology
research is still in its infancy, canine studies have already
helped advance the understanding of human tumor biology
and treatment. Through continued efforts to improve our
understanding of canine tumor biology, and careful application
of the canine comparative oncology model, we expect that man’s
best friend will be key to reducing the global burden of cancer
and improving cancer care.
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